KIF2C and hepatocellular carcinoma: Studies in hepatocellular carcinoma (HCC) [102], glioma [103,104], kidney renal clear cell carcinoma (KIRC) [105] and pancreatic ductal adenocarcinoma (PDAC) [99] suggest that a high expression of KIF2C interferes with proper immune cell infiltration by recruiting increased numbers of tumor-associated macrophages, cancer-associated fibroblasts, myeloid-derived suppressor cells and Treg into the TME [95].